reMYND has a proprietary phenotypic screening platform to discover disease-modifying small molecule treatments and their corresponding novel targets:
Reducing as well aBeta as Tau pathology over-time, and in addition providing immediate cognitive improvement by restoring synaptic function
Durably reversing diabetes in Type 1 and 2, by improving beta-cell health and insulin signalling
Discovery programs with in vivo proof-of-concept in Parkinson’s, Epilepsy and Huntington’s
Our Contract Research Organization (CRO) helps our clients assess the effects of their experimental Alzheimer treatments in our proprietary mouse models.
We serve the majority of the Top 10 pharmaco’s worldwide with clients in the US, Europe and Japan. We have provided pivotal in-vivo proof-of-concept data for several candidate drugs currently in clinical development, and work actively together with Dr. Sugimoto, the inventor of Aricept. We have helped our clients to be the first to demonstrate the synergistic effect of a BACE inhibitor and an aBeta antibody, the effect of Tau antibody on aBeta, the effect of donepezil on brain Abeta, …
reMYND was founded in 2002 as a spin-off CRO from the University of Leuven.
We strongly believe that, by taking the lead and working together, we can provide innovative solutions to address key challenges at the root that have shown to be unsolvable so far.
reMYND has been substantially supported by grants from VLAIO, the European Union and The Michael J Fox Foundation.